$4.16
1.71% yesterday
Nasdaq, Apr 24, 10:01 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$4.16
+0.24 6.12% 1M
-5.82 58.33% 6M
-4.18 50.12% YTD
-14.30 77.46% 1Y
-78.24 94.95% 3Y
-754.27 99.45% 5Y
-1,759.99 99.76% 10Y
Nasdaq, Closing price Thu, Apr 24 2025
+0.07 1.71%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $40.73m
Enterprise Value $333.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.98
P/S ratio (TTM) P/S ratio 0.49
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 184.12%
Revenue (TTM) Revenue $83.81m
EBIT (operating result TTM) EBIT $-267.70m
Free Cash Flow (TTM) Free Cash Flow $-262.62m
Cash position $62.34m
EPS (TTM) EPS $-24.86
P/E forward negative
P/S forward 0.14
EV/Sales forward 1.13
Short interest 18.24%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a bluebird bio, Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a bluebird bio, Inc. forecast:

Buy
20%
Hold
80%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
84 84
184% 184%
100%
- Direct Costs 97 97
169% 169%
116%
-13 -13
101% 101%
-16%
- Selling and Administrative Expenses 99 99
35% 35%
118%
- Research and Development Expense 94 94
45% 45%
112%
-206 -206
37% 37%
-246%
- Depreciation and Amortization 61 61
411% 411%
73%
EBIT (Operating Income) EBIT -268 -268
22% 22%
-319%
Net Profit -241 -241
18% 18%
-287%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Neutral
Business Wire
9 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (t...
Positive
Reuters
28 days ago
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Positive
Market Watch
28 days ago
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 248
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today